The Human Use Medicines Committee (CHMP) of the European Medicines Agency (EMA) has recommended the authorization of Pagliflozine/Linagliptin, recorded by the Alliance for Boehringer Ingelheim and Lilly diabetes with the name of Glyxambi for the treatment of adultswith type 2 diabetes.
The objective of the drug is to improve blood glucose control when the use of metformin and/or sulfonylurea next to one of the Glyxambi components does not provide sufficient control, or when the patient is already in treatment with a free combination of JardiaAnd I leave.
This recommendation is based on data from three phase III clinical trials that have evaluated their efficacy and safety in patients with DM2.Glyxambi is a unique tablet that combines Jardiance (Pagliflozine), sodium and glucose collection inhibitor of type 2 (SGLT2) and suit (linagliptin), peptidase 4 (DPP-4) dipeptile inhibitor (DPP-4).“We are excited about the positive resolution.
We believe that this treatment for type 2 diabetes will offer European patients and doctors another useful option to improve glycemic control.Boehringer Ingelheim and Lilly hope to receive the final marketing authorization of the European Commission in the coming months, ”said the world vice president of Medicine from the therapeutic area of Boehringer Ingelheim, Hans-Juergen Woerle.